Literature DB >> 20087683

High-dose cyclophosphamide for autoimmunity and alloimmunity.

Robert A Brodsky1.   

Abstract

High-dose cyclophosphamide (high-CY) is a potent immunosuppressive regimen that is increasingly used to mitigate both autoimmune and alloimmune conditions. Differential expression of aldehyde dehydrogenase between hematopoietic stem cells and lymphocytes accounts for the differential sensitivity of these cells to high-CY and explains why this regimen is immunosuppressive but not myeloablative. This article describes the clinical translation of high-CY for the treatment of autoimmune and alloimmune conditions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20087683     DOI: 10.1007/s12026-009-8149-y

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  38 in total

1.  High-dose cyclophosphamide for refractory autoimmune hemolytic anemia.

Authors:  Victor M Moyo; Douglas Smith; Isadore Brodsky; Pamela Crilley; Richard J Jones; Robert A Brodsky
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

2.  Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis.

Authors:  Daniel B Drachman; Robert N Adams; Rong Hu; Richard J Jones; Robert A Brodsky
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

3.  Recovery from aplastic anemia after treatment with cyclophosphamide.

Authors:  D T Baran; P F Griner; M R Klemperer
Journal:  N Engl J Med       Date:  1976-12-30       Impact factor: 91.245

Review 4.  Genetic dissection of retinoid dehydrogenases.

Authors:  G Duester
Journal:  Chem Biol Interact       Date:  2001-01-30       Impact factor: 5.192

Review 5.  Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions.

Authors:  A Tyndall; R Saccardi
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

Review 6.  Aplastic anaemia.

Authors:  Robert A Brodsky; Richard J Jones
Journal:  Lancet       Date:  2005 May 7-13       Impact factor: 79.321

Review 7.  Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: advantages and disadvantages.

Authors:  Robert A Brodsky; Richard J Jones
Journal:  Autoimmunity       Date:  2008-12       Impact factor: 2.815

Review 8.  Cyclophosphamide and cancer: golden anniversary.

Authors:  Ashkan Emadi; Richard J Jones; Robert A Brodsky
Journal:  Nat Rev Clin Oncol       Date:  2009-09-29       Impact factor: 66.675

9.  Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation.

Authors:  R A Brodsky; L L Sensenbrenner; R J Jones
Journal:  Blood       Date:  1996-01-15       Impact factor: 22.113

10.  Assessment of aldehyde dehydrogenase in viable cells.

Authors:  R J Jones; J P Barber; M S Vala; M I Collector; S H Kaufmann; S M Ludeman; O M Colvin; J Hilton
Journal:  Blood       Date:  1995-05-15       Impact factor: 22.113

View more
  15 in total

1.  Cyclophosphamide for rapid-onset obesity, hypothalamic dysfunction, hypoventilation, and autonomic dysregulation syndrome.

Authors:  Ido Paz-Priel; David W Cooke; Allen R Chen
Journal:  J Pediatr       Date:  2010-08-21       Impact factor: 4.406

2.  High-dose cyclophosphamide without stem cell rescue for the treatment of refractory Behcet's disease.

Authors:  Charles F Henderson; Robert A Brodsky; Richard J Jones; Stuart M Levine
Journal:  Semin Arthritis Rheum       Date:  2011-02-03       Impact factor: 5.532

3.  Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia.

Authors:  Yvette L Kasamon; Robert A Brodsky; Michael J Borowitz; Richard F Ambinder; Pamela A Crilley; Steve Y Cho; Hua-ling Tsai; B Douglas Smith; Douglas E Gladstone; Hetty E Carraway; Carol Ann Huff; William H Matsui; Javier Bolaños-Meade; Richard J Jones; Lode J Swinnen
Journal:  Leuk Lymphoma       Date:  2012-08-17

4.  Diabetes mellitus increases the susceptibility to encephalitozoonosis in mice.

Authors:  Aldo Francisco Neto; Paulo Ricardo Dell'Armelina Rocha; Elizabeth Christina Perez; José Guilherme Xavier; Giovani Bravin Peres; Diva Denelle Spadacci-Morena; Anuska Marcelino Alvares-Saraiva; Maria Anete Lallo
Journal:  PLoS One       Date:  2017-11-01       Impact factor: 3.240

5.  Inhibition of chemotherapy-induced apoptosis of testicular cells by squid ink polysaccharide.

Authors:  Yi-Peng Gu; Xiao-Mei Yang; Zhen-Hua Duan; Ping Luo; Jiang-Hua Shang; Wei Xiao; Ye-Xing Tao; Da-Yan Zhang; Yun-Bo Zhang; Hua-Zhong Liu
Journal:  Exp Ther Med       Date:  2017-10-18       Impact factor: 2.447

6.  Low-dose oral cyclophosphamide therapy reduces atherosclerosis progression by decreasing inflammatory cells in a murine model of atherosclerosis.

Authors:  Yayoi Sato-Okabayashi; Kikuo Isoda; Beate Heissig; Tomoyasu Kadoguchi; Koji Akita; Kenichi Kitamura; Kazunori Shimada; Koichi Hattori; Hiroyuki Daida
Journal:  Int J Cardiol Heart Vasc       Date:  2020-05-10

Review 7.  Differential Effects of MS Therapeutics on B Cells-Implications for Their Use and Failure in AQP4-Positive NMOSD Patients.

Authors:  Jan Traub; Silke Häusser-Kinzel; Martin S Weber
Journal:  Int J Mol Sci       Date:  2020-07-16       Impact factor: 5.923

8.  Cyclophosphamide Treatment Mimics Sub-Lethal Infections With Encephalitozoon intestinalis in Immunocompromised Individuals.

Authors:  Maria Lucia Costa de Moura; Anuska Marcelino Alvares-Saraiva; Elizabeth Cristina Pérez; José Guilherme Xavier; Diva Denelle Spadacci-Morena; Carla Renata Serantoni Moysés; Paulo Ricardo Dell'Armelina Rocha; Maria Anete Lallo
Journal:  Front Microbiol       Date:  2019-09-25       Impact factor: 5.640

Review 9.  Combination therapy: A feasibility strategy for CAR-T cell therapy in the treatment of solid tumors.

Authors:  Jinjing Xu; Yali Wang; Jing Shi; Juan Liu; Qingguo Li; Longzhou Chen
Journal:  Oncol Lett       Date:  2018-06-11       Impact factor: 3.111

10.  Compatibility effects of ginseng and Ligustrum lucidum Ait herb pair on hematopoietic recovery in mice with cyclophosphamide-induced myelosuppression and its material basis.

Authors:  Jiahong Han; Min Dai; Yan Zhao; Enbo Cai; Lianxue Zhang; Xiaohuan Jia; Nian Sun; Xuan Fei; Hui Shu
Journal:  J Ginseng Res       Date:  2019-01-11       Impact factor: 6.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.